Australia markets closed

Mauna Kea Technologies SA (0P5I.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.3890-0.0205 (-5.01%)
As of 10:44AM BST. Market open.

Mauna Kea Technologies SA

9, rue d'Enghien
Paris 75010
France
33 1 48 24 03 45
https://www.maunakeatech.com

Sector(s)
Industry
Full-time employees67

Key executives

NameTitlePayExercisedYear born
Mr. Alexandre Loiseau Ph.D.Co-Founder, CEO & Chairman172.64kN/AN/A
Mr. Come de La Tour du PinChief Financial OfficerN/AN/AN/A
Ms. Nathalie LecoqChief Operating OfficerN/AN/AN/A
Mr. Frederic Banegas Ph.D.Chief Technology OfficerN/AN/AN/A
Mr. François Lacombe Ph.D.Chief Scientific OfficerN/AN/AN/A
Mr. Daryl DonatelliVice President of Global Marketing & U.S. SalesN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Mauna Kea Technologies SA develops and markets medical devices in Europe and internationally. The company offers range of medical devices, which includes gastroenterology, pulmonology, urology, and drug development. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform which enables physicians to monitor progression of disease over time, assess point-in-time reactions, classify indeterminate areas, and guide surgical interventions. The company was incorporated in 2000 and is headquartered in Paris, France.

Corporate governance

Mauna Kea Technologies SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.